ORPHA:319480
Acute myeloid leukemia with CEBPA somatic mutations
Also known as: AML with CEBPA somatic mutations
Publications
74
41.6th percentile
Trials
0
Interventional, condition-specific
Researchers
528
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A subtype of acute myeloid leukemia with recurrent genetic abnormalities, characterized by clonal proliferation of myeloid blasts harboring somatic mutations of the CEBPA gene in the bone marrow, blood and, rarely, other tissues. It can present with anemia, thrombocytopenia, and other nonspecific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement (gingivitis, ).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017894
- UMLS:C4707178
- NCIT:C82433
Additional Mondo synonyms (7)
AML with mutated CEBPA · acute myeloid Leukaemia with mutated CEBPA · acute myeloid Leukaemia with non-germline mutated CEBPA · acute myeloid Leukemia with mutated CEBPA · acute myeloid Leukemia with non-germline mutated CEBPA · non-familial acute myeloid leukaemia with mutated CEBPA · non-familial acute myeloid leukemia with mutated CEBPA
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
74 matched papers (31 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 2498 for broader category acute myeloid leukemia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
74
74 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
74 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
31 in the last 10 years · high confidence · 41.6th percentile (publications denominator)
Phrase hits: 74 · MeSH hits: 0
Who's working on it?
528
Distinct author names in 74 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01DiNardo CD4 papers · 2019
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: cdinardo@mdanderson.org.
Papers in Europe PMC - 02Godley LA4 papers · 2016
Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Research Center, University of Chicago, Chicago, IL.
Papers in Europe PMC - 03Churpek JE3 papers · 2016
Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Research Center, University of Chicago, Chicago, IL.
Papers in Europe PMC - 04Cortes JE3 papers · 2018
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Papers in Europe PMC - 05
- 06Kantarjian HM3 papers · 2018
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Papers in Europe PMC - 07Kolb EA3 papers · 2025
Nemours Center for Cancer and Blood Disorders, Alfred I. duPont Hospital for Children , Wilmington, DE , USA.
Papers in Europe PMC - 08Larson RA3 papers · 2014Papers in Europe PMC
- 09Schlenk RF3 papers · 2017
Department of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. richard.schlenk@uniklinik-ulm.de.
Papers in Europe PMC - 10Alonzo T2 papers · 2025
University of Southern California Keck School of Med, Los Angeles, CA, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 2,498 trials are registered for acute myeloid leukemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 October 2026 · last trial check 26 October 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5498 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
2,498 interventional trials matched acute myeloid leukemia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: acute myeloid leukemia
2,498
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05657639·RECRUITING·CAV Regimen for R/R AML
Conditions: Acute Myeloid Leukemia·Matched via name phrase
- NCT06741722·RECRUITING·Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Conditions: AML · Relapsed Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia·Matched via name phrase
- NCT03670966·RECRUITING·211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia in Remission · Chronic Myelomonocytic Leukemia·Matched via name phrase
- NCT05875805·RECRUITING·A Telehealth Advance Care Planning Intervention
Conditions: Myeloid Malignancy · Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasm·Matched via name phrase
- NCT06660368·RECRUITING·BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)·Matched via name phrase
- NCT04628026·RECRUITING·Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Conditions: Acute Myeloid Leukemia·Matched via name phrase
- NCT07270978·RECRUITING·Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Conditions: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasm·Matched via name phrase
- NCT07726576·NOT YET RECRUITING·Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia
Conditions: Leukemia, Myeloid, Acute·Matched via name phrase
- NCT07028086·RECRUITING·VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Conditions: Acute Myeloid Leukemia · Myeloid Sarcoma·Matched via name phrase
- NCT06504459·RECRUITING·Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Conditions: Acute Monocytic Leukemia · Acute Myeloid Leukemia·Matched via name phrase
- NCT03970096·RECRUITING·Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndrome·Matched via name phrase
- NCT07565220·RECRUITING·Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Conditions: Acute Lymphocytic Leukemia (ALL) · Acute Myeloid Leukemia (AML) · Acute Leukemia · Myelodysplastic Syndrome(MDS)·Matched via name phrase
- NCT07121140·RECRUITING·Home Blood Transfusions
Conditions: Hematologic Malignancy · Myelodysplastic Syndromes · Acute Myeloid Leukemia · Transfusion Dependent Cytopenias·Matched via name phrase
- NCT07828535·NOT YET RECRUITING·Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML
Conditions: Acute Myeloid Leukemia (AML)·Matched via name phrase
- NCT07320235·RECRUITING·Imetelstat Combinations in Relapsed AML
Conditions: Relapsed Acute Myeloid Leukemia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Acute myeloid leukemia with CEBPA somatic mutations — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acute myeloid leukemia with CEBPA somatic mutations" OR "AML with CEBPA somatic mutations" OR "AML with mutated CEBPA" OR "acute myeloid Leukaemia with mutated CEBPA" OR "acute myeloid Leukaemia with non-germline mutated CEBPA" OR "acute myeloid Leukemia with mutated CEBPA" OR "acute myeloid Leukemia with non-germline mutated CEBPA" OR "non-familial acute myeloid leukaemia with mutated CEBPA" OR "non-familial acute myeloid leukemia with mutated CEBPA"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acute myeloid leukemia with CEBPA somatic mutations" OR "AML with CEBPA somatic mutations" OR "AML with mutated CEBPA" OR "acute myeloid Leukaemia with mutated CEBPA" OR "acute myeloid Leukaemia with non-germline mutated CEBPA" OR "acute myeloid Leukemia with mutated CEBPA" OR "acute myeloid Leukemia with non-germline mutated CEBPA" OR "non-familial acute myeloid leukaemia with mutated CEBPA" OR "non-familial acute myeloid leukemia with mutated CEBPA"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"acute myeloid leukemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:27:46.955Z
